Oremten (Emtricitabine, Tenofovir Disoproxil)

Emtricitabine, the active ingredient in Oremten, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It treats HIV-1 infection in combination with other antiretroviral agents. GNH USA supplies Oremten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oremten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oremten combines emtricitabine and tenofovir disoproxil to target the reverse‑transcriptase pathway in HIV infection.

- HIV‑1 infection: improves viral suppression when used with other antiretrovirals. - Post‑exposure prophylaxis (PEP): reduces risk of HIV acquisition after potential exposure. - Pre‑exposure prophylaxis (PrEP): lowers the incidence of HIV infection in high‑risk individuals. - Chronic hepatitis B infection: contributes to viral load reduction when combined with other antivirals.

Common Side Effects: -  ...   - … … … … … … ...  t…  

...